China Accepts Indian Inspectors To Check Quality Of Bulk Drugs
This article was originally published in PharmAsia News
China and India are launching a cooperative drug inspection effort that kicks off with India's Ministry of Health sending a team to China to inspect bulk drugs. India relies on China-produced bulk drugs for much of its drug production, but the Drug Controller General of India recently questioned the quality of those supplies. China is the source of 70 percent of bulk drugs imported by India. An industry official suggested the emphasis has been too much on the cheaper price of imported drugs and not enough on their quality. (Click here for more
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.